Production of transforming growth factor-alpha in human tumour cell lines. 1989

K Imanishi, and K Yamaguchi, and M Suzuki, and S Honda, and N Yanaihara, and K Abe
Growth Factor Division, National Cancer Research Institute, Tokyo, Japan.

Forty-one human tumour cell lines were examined for the production of epidermal growth factor (EGF)/transforming growth factor (TGF)-alpha-like activity (EGF/TGF-alpha-LA), immunoreactive (IR-) EGF and IR-TGF-alpha. EGF/TGF-alpha-LA was determined by radioreceptor assay, in which the factors with capacity to bind to EGF receptor could be detected. IR-EGF and IR-TGF-alpha were determined by the respective radioimmunoassays. Both EGF/TGF-alpha-LA and IR-TGF-alpha were detected in 11 tumour cell lines. The levels of EGF/TGF-alpha-LA correlated well with those of IR-TGF-alpha. A small amount of IR-TGF-alpha was detected in five other lines. In contrast, IR-EGF was not detectable in any of the 41. Consequently, it can be concluded that EGF/TGF-alpha-LA produced by human tumour cells is mainly TGF-alpha rather than EGF. It was also revealed that melanoma cell lines produce a large amount of TGF-alpha frequently. Gel filtration studies revealed that TGF-alpha produced by melanoma cell lines was identical to human (h) TGF-alpha(1-50), except for one line, in which IR-TGF-alpha with a different molecular size was detected. Northern blot analysis revealed that bands corresponding to hTGF-alpha mRNA were present in melanoma cell lines producing a large amount of IR-TGF-alpha, indicating that the TGF-alpha produced is the product of hTGF-alpha gene. Further studies are required to discover the actual biological roles of TGF-alpha produced by melanoma cells as well as other types of cancer cells.

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002850 Chromatography, Gel Chromatography on non-ionic gels without regard to the mechanism of solute discrimination. Chromatography, Exclusion,Chromatography, Gel Permeation,Chromatography, Molecular Sieve,Gel Filtration,Gel Filtration Chromatography,Chromatography, Size Exclusion,Exclusion Chromatography,Gel Chromatography,Gel Permeation Chromatography,Molecular Sieve Chromatography,Chromatography, Gel Filtration,Exclusion Chromatography, Size,Filtration Chromatography, Gel,Filtration, Gel,Sieve Chromatography, Molecular,Size Exclusion Chromatography
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015152 Blotting, Northern Detection of RNA that has been electrophoretically separated and immobilized by blotting on nitrocellulose or other type of paper or nylon membrane followed by hybridization with labeled NUCLEIC ACID PROBES. Northern Blotting,Blot, Northern,Northern Blot,Blots, Northern,Blottings, Northern,Northern Blots,Northern Blottings
D015291 Transforming Growth Factors Hormonally active polypeptides that can induce the transformed phenotype when added to normal, non-transformed cells. They have been found in culture fluids from retrovirally transformed cells and in tumor-derived cells as well as in non-neoplastic sources. Their transforming activities are due to the simultaneous action of two otherwise unrelated factors, TRANSFORMING GROWTH FACTOR ALPHA and TRANSFORMING GROWTH FACTOR BETA. Transforming Growth Factor,Factor, Transforming Growth,Factors, Transforming Growth,Growth Factor, Transforming,Growth Factors, Transforming

Related Publications

K Imanishi, and K Yamaguchi, and M Suzuki, and S Honda, and N Yanaihara, and K Abe
January 1990, Anticancer research,
K Imanishi, and K Yamaguchi, and M Suzuki, and S Honda, and N Yanaihara, and K Abe
January 1994, British journal of cancer,
K Imanishi, and K Yamaguchi, and M Suzuki, and S Honda, and N Yanaihara, and K Abe
December 1989, Japanese journal of clinical oncology,
K Imanishi, and K Yamaguchi, and M Suzuki, and S Honda, and N Yanaihara, and K Abe
February 1991, International journal of cancer,
K Imanishi, and K Yamaguchi, and M Suzuki, and S Honda, and N Yanaihara, and K Abe
January 1992, Cancer research,
K Imanishi, and K Yamaguchi, and M Suzuki, and S Honda, and N Yanaihara, and K Abe
June 1998, Cytokine,
K Imanishi, and K Yamaguchi, and M Suzuki, and S Honda, and N Yanaihara, and K Abe
January 1994, Growth factors (Chur, Switzerland),
K Imanishi, and K Yamaguchi, and M Suzuki, and S Honda, and N Yanaihara, and K Abe
October 1993, Leukemia,
K Imanishi, and K Yamaguchi, and M Suzuki, and S Honda, and N Yanaihara, and K Abe
January 1987, Nature,
K Imanishi, and K Yamaguchi, and M Suzuki, and S Honda, and N Yanaihara, and K Abe
January 1989, The Prostate,
Copied contents to your clipboard!